Epidermolysis bullosa gene therapy - Holostem/University of Modena and Reggio Emilia

Drug Profile

Epidermolysis bullosa gene therapy - Holostem/University of Modena and Reggio Emilia

Alternative Names: ATMP - Holostem Terapie Avanzate; Epidermolysis bullosa ex vivo gene therapy; Hologene 7

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Holostem Terapie Avanzate; University of Modena and Reggio Emilia
  • Developer Holostem Terapie Avanzate
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Epidermolysis bullosa

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for clinical-Phase-Unknown development in Epidermolysis-bullosa in Italy
  • 06 Sep 2017 Holostem Terapie plans a phase I/II trial for Epidermolysis bullosa in Austria (EudraCT2016-000095-17)
  • 30 Jan 2017 Phase-I/II clinical trials in Epidermolysis bullosa (In children, In adults, In adolescents) in Austria (NCT02984085)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top